Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27770345 | 0.98 | ALDH1A1 (0.71) | CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1 | |
| SCHEMBL1381550 | 0.98 | ALDH1A1 (0.70) | CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1 | |
| SCHEMBL10722398 | 0.92 | HPGD (0.67) | CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1 | |
| SCHEMBL8150803 | 0.91 | HPGD (0.76) | CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1 | |
| SCHEMBL5474202 | 0.91 | ALDH1A1 (0.71) | CYP1A2CYP2D6CYP2C9ALDH1A1MEN1 | |
| SCHEMBL2555571 | 0.89 | CCR3 (0.67) | CYP1A2CYP2D6CYP2C9ALDH1A1KDM4E | |
| SCHEMBL1384427 | 0.89 | ALDH1A1 (0.72) | ALDH1A1MEN1KMT2AHPGDKDM4E | |
| SCHEMBL3642214 | 0.87 | CYP1A2 (0.65) | CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1 | |
| SCHEMBL11341680 | 0.86 | HDAC2 (0.76) | ALDH1A1NPSR1POLBHPGDCD274 | |
| SCHEMBL4488723 | 0.86 | CYP1A2 (0.76) | CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | claimed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| JP-2002532414-A | — | — | 2002-10-02 | — | — | JP | claimed |
| EP-1140046-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035435-A9 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER LAMBERT CO (US) | 2001-03-22 | — | — | WO | claimed |
| WO-2000035435-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| WO-1998037881-A1 | METHOD OF TREATING OR PREVENTING SEPTIC SHOCK BY ADMINISTERING A MEK INHIBITOR | WARNER LAMBERT COMPANY (US) | 1998-09-03 | — | — | WO | claimed |
| WO-2024246764-A1 | NOVEL BENZAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 삼진제약주식회사 | 2024-12-05 | — | — | WO | disclosed |
| WO-2024166024-A1 | NEW COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 삼진제약주식회사 | 2024-08-15 | — | — | WO | disclosed |
| US-20240092790-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-21 | — | — | US | disclosed |
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| CN-109476633-A | The inhibitor of tryptophan 2,3- dioxygenase | 荷兰转化研究中心有限责任公司 | 2019-03-15 | — | — | CN | disclosed |
| WO-2011145035-A1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | INDIAN INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-11-24 | — | — | WO | disclosed |
| US-7019033-B2 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | WARNER-LAMBERT COMPANY (US) | 2006-03-28 | — | — | US | disclosed |
| US-6492363-B2 | FOR THERAPY OF CANCER AND OTHER PROLIFERATIVE DISEASES SUCH AS INFLAMMATION, PSORIASIS AND RESTENOSIS, AS WELL AS STROKE, HEART FAILURE, AND IMMUNODEFICIENCY DISORDERS | WARNER-LAMBERT COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-6310060-B1 | FOR USE AS ANTIPROLIFERATIVE AGENT FOR USE AGAINST CANCER, PSORIASIS, RESTENOSIS, AUTOIMMUNE DISEASE, OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2001-10-30 | — | — | US | disclosed |
| WO-1998037881-A1 | METHOD OF TREATING OR PREVENTING SEPTIC SHOCK BY ADMINISTERING A MEK INHIBITOR | WARNER LAMBERT COMPANY (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092790-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | CYP1A2 733/4885CYP2D6 1865/4885CYP2C9 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.